

Clinical Trial Protocol

Iranian Registry of Clinical Trials

17 Sep 2026

Evaluation of the effect of uterine flushing with human chorionic gonadotropin (hCG) on biochemical and clinical pregnancy rate in the IUI cycle of couples with idiopathic infertility

Protocol summary

Study aim

Evaluation of the effect of uterine flushing with human chorionic gonadotropin (hCG) on biochemical and clinical pregnancy rate in the IUI cycle of couples with idiopathic infertility

Design

The present study will be a randomized controlled trial. The method of sampling from the population will be Simple random sampling and couples with the diagnosis of unexplained infertility will be included in the study. There are 80 couples with unexplained infertility divided to intervention and control groups (40 patients in each group) and the age of all members is between 20-38 years.

Settings and conduct

This study will be conducted in the field of infertility treatment on 80 patients referred to the infertility clinic of Alzahra Hospital in Tabriz. Patients will be randomly divided into two groups of 40 people. The control group will receive 10,000 units of hCG intramuscularly. And the intervention group, in addition to intramuscular injection, two hours before intrauterine sperm insemination (IUI), 1000 units of hCG will be diluted in half a cc of normal saline and injected directly into the uterine cavity.

Participants/Inclusion and exclusion criteria

In this study, women diagnosed with primary or secondary infertility between the ages of 20 and 38 will be included in the study if they have consent, and if they have blocked fallopian tubes or any hormonal disorder, they will be prohibited from entering the study.

Intervention groups

we inject 10000 IU intra muscular hCG in both groups. 34-36 hours later the IUI will be performed as usual. 2 hours before the IUI, In intervention group we Dilute 1000 IU hCG in 0.5 cc of normal saline and inject directly in the uterus cavity but in control group we just inject 0.5 cc of normal saline into the uterus.

Main outcome variables

Clinical pregnancy is considered as the main outcome of this study.

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20220702055335N1**

Registration date: **2022-08-09, 1401/05/18**

Registration timing: **registered_while_recruiting**

Last update: **2022-08-09, 1401/05/18**

Update count: **0**

Registration date

2022-08-09, 1401/05/18

Registrant information

Name

Parvin Hakimi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 41 3553 9161

Email address

parvin.hakimi56@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-08-06, 1401/05/15

Expected recruitment end date

2023-08-06, 1402/05/15

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of the effect of uterine flushing with human chorionic gonadotropin (hCG) on biochemical and clinical pregnancy rate in the IUI cycle of couples with idiopathic infertility

Public title

Evaluation of the effect of uterine flushing with human chorionic gonadotropin (hCG) on biochemical and clinical pregnancy rate in the IUI cycle of couples with idiopathic infertility

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Having an informed consent to participate in the study
Unexplained infertility diagnosis
The health of the uterus structure
Normal sperm analysis
Women between 20 and 38 years old
The presence of ovulation

Exclusion criteria:

unsatisfaction for the participation of study
Moderate to severe endometriosis
hyper prolactinemia
Hyperthyroidism
Hypothyroidism
Ovarian Cysts
Kidney and liver failure
Blocked fallopian tubes
Increased FSH

AgeFrom **20 years** old to **38 years** old**Gender**

Female

Phase

3

Groups that have been masked

- Outcome assessor
- Data analyser

Sample sizeTarget sample size: **80****Randomization (investigator's opinion)**

Randomized

Randomization description

Patients who meet the inclusion criteria are divided into two intervention groups using simple randomization method. The randomization method used in this study is the use of a table of random numbers. Random number table is a set of numbers that is generated without a specific pattern or order and they generated randomly and they are formed in a table. In first the direction of reading the numbers was specified. To read the numbers, random numbers are read from the left side of the table, then even numbers extracted from the table are allocated to intervention group 1 and odd numbers extracted from the table are allocated to intervention group 2.

Blinding (investigator's opinion)

Double blinded

Blinding description

Before prescribing the drug to the patient, the plan is introduced and written consent is received. Study at the

patient level, outcome assessor and statistical analyzer of the results will be blinded.

Placebo

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committee Of Tabriz University Of Medical Sciences

Street address

Third Floor, Central Building of Number2, Golgasht Street

City

Tabriz

Province

East Azarbaijan

Postal code

5166616471

Approval date

2022-06-01, 1401/03/11

Ethics committee reference number

IR.TBZMED.REC.1401.233

Health conditions studied**1****Description of health condition studied**

Female infertility

ICD-10 code

N97.9

ICD-10 code description

Female infertility, unspecified

Primary outcomes**1****Description**

clinical pregnancy rate

Timepoint

28 days after transfer

Method of measurement

vaginal sonography

2**Description**

chemical pregnancy rate

Timepoint

14 days after transfer

Method of measurement

BhCG test

Secondary outcomes

empty

Intervention groups**1****Description**

Control group: At the beginning of menstruation and on the third day, an ultrasound will be performed, and from the third day of menstruation, 1 or 2 tablets of letrozole 2.5 mg will be prescribed daily for 5 days. Then, according to the age and state of ovarian reserve, We may inject Cinnal-F ampoule (Cina Gene Pharmaceuticals) 75 units subcutaneously on days 6, 8 and 10. Then on the 10th or 11th day, an ultrasound will be performed and if one or two follicles with a size larger than 18-20 mm and endometrial thickness greater than 7 mm are observed, 10,000 units of hCG will be injected intramuscularly. 34-36 hours later the IUI will be performed as usual. In this group, two hours before IUI, 0.5 cc of normal saline will be injected into the uterus as a placebo.

Category

Treatment - Drugs

2**Description**

intervention group: At the beginning of menstruation and on the third day, an ultrasound will be performed, and from the third day of menstruation, 1 or 2 tablets of letrozole 2.5 mg will be prescribed daily for 5 days. Then, according to the age and state of ovarian reserve, We may inject Cinnal-F ampoule (Cina Gene Pharmaceuticals) 75 units subcutaneously on days 6, 8 and 10. Then on the 10th or 11th day, an ultrasound will be performed and if one or two follicles with a size larger than 18-20 mm and endometrial thickness greater than 7 mm are observed, 10,000 units of hCG will be injected intramuscularly. 34-36 hours later the IUI will be performed as usual. In this group, two hours before IUI, 1000 IU hCG will be diluted in 0.5 cc of normal saline and will be injected directly in the uterus cavity.

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Alzahra Hospital

Full name of responsible person

Dr.Parvin Hakimi

Street address

Alzahra Hospital, South Artesh St.,Tabriz, iran

City

Tabriz

Province

East Azarbaijan

Postal code

5138665793

Phone

+98 41 3553 9161

Email

lahroudin@gmail.com

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Vice chancellor for Research,Tabriz

Full name of responsible person

Dr.Parviz Shahabi

Street address

No. 2 Central Building,Tabriz University of Medical Sciences, Golgasht Street, Tabriz

City

Tabriz

Province

East Azarbaijan

Postal code

5138665793

Phone

+98 41 3335 7310

Email

research-vice@tbzmed.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Vice chancellor for Research,Tabriz

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Tabriz University of Medical Sciences

Full name of responsible person

Parvin Hakimi

Position

Associate Professor of Obstetrics Gynecology

Latest degree

Subspecialist

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Tabriz University Of Medical Sciences, Golgasht Street

City

Tabriz

Province

East Azarbaijan

Postal code

5138665793

Phone

+98 35519161

Email

lahroudin@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Parvin Hakimi

Position

Associate Professor of Obstetrics Gynecology

Latest degree

Subspecialist

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Tabriz University Of Medical Sciences, Golgasht Street

City

Tabriz

Province

East Azarbaijan

Postal code

5138665793

Phone

+98 35519161

Email

lahroudin@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Parvin Hakimi

Position

Associate Professor of Obstetrics Gynecology

Latest degree

Subspecialist

Other areas of specialty/work

Gynecology and Obstetrics

Street address

Tabriz University Of Medical Sciences, Golgasht Street

City

Tabriz

Province

East Azarbaijan

Postal code

5138665793

Phone

+98 35519161

Email

lahroudin@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available